Moderna (NASDAQ:MRNA): Q2 net loss of $135.1M
Revenue of $13.08M (-54.7% Y/Y) misses by $5.31M.
Wednesday, August 7, 2019
Surgery Partners EPS misses by $0.14, misses on revenue
Surgery Partners (NASDAQ:SGRY): Q2 Non-GAAP EPS of -$0.29 misses by $0.14; GAAP EPS of -$0.59 misses by $0.33.
Revenue of $445.4M (+2.0% Y/Y) misses by $5.49M.
Rocket Pharmaceuticals EPS beats by $0.23
Rocket Pharmaceuticals (NASDAQ:RCKT): Q2 GAAP EPS of -$0.38 beats by $0.23.
Cash, equivalents and investments of $257.78M.
Ra Pharmaceuticals EPS misses by $0.03
Ra Pharmaceuticals (NASDAQ:RARX): Q2 GAAP EPS of -$0.52 misses by $0.03.
Cash and cash equivalents of $173.6M
Madrigal Pharmaceuticals EPS misses by $0.21
Madrigal Pharmaceuticals (NASDAQ:MDGL): Q2 GAAP EPS of -$1.28 misses by $0.21.
Cash and equivalents of $466.4M
ADVANZ PHARMA EPS misses by $0.45, beats on revenue
ADVANZ PHARMA (OTCPK:CXRXF): Q2 GAAP EPS of -$0.90 misses by $0.45.
Revenue of $131.08M (-6.0% Y/Y) beats by $4.08M.
Weight Watchers +23% on strong outlook
Weight Watchers (NASDAQ:WW) sails higher in premarket trading after setting favorable guidance alongside its Q2 report.
The company expects full-year revenue of at least $1.40B vs. $1.40B consensus and EPS of $1.55 to $1.70 vs. $1.52 consensus.
Weight Watchers ended Q2 with 4.6M paid subscribers vs. 4.5M a year ago. Digital subscribers were 3.2M vs. 2.9M a year ago.
Shares of WW are up 22.80% premarket to $25.80.
Previously: Weight Watchers EPS beats by $0.13, misses on revenue (Aug. 6)
Subscribe to:
Posts (Atom)